<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-14673R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0009287</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology/Antigen Processing and Recognition</subject><subject>Immunology/Autoimmunity</subject><subject>Neuroscience/Neurobiology of Disease and Regeneration</subject></subj-group></article-categories><title-group><article-title>Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population</article-title><alt-title alt-title-type="running-head">LMP2 60HH Variant in MS</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mishto</surname><given-names>Michele</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bellavista</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ligorio</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Textoris-Taube</surname><given-names>Kathrin</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Santoro</surname><given-names>Aurelia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Giordano</surname><given-names>Mara</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>D'Alfonso</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>List&#x000ec;</surname><given-names>Florinda</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nacmias</surname><given-names>Benedetta</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cellini</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Leone</surname><given-names>Maurizio</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Grimaldi</surname><given-names>Luigi M.E.</given-names></name><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fenoglio</surname><given-names>Chiara</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Esposito</surname><given-names>Federica</given-names></name><xref ref-type="aff" rid="aff11"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Martinelli-Boneschi</surname><given-names>Filippo</given-names></name><xref ref-type="aff" rid="aff11"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Galimberti</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Scarpini</surname><given-names>Elio</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Seifert</surname><given-names>Ulrike</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Amato</surname><given-names>Maria Pia</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Caruso</surname><given-names>Calogero</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Foschini</surname><given-names>Maria P.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kloetzel</surname><given-names>Peter M.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Franceschi</surname><given-names>Claudio</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Experimental Pathology, University of Bologna, Bologna, Italy</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Interdepartmental Center for Studies on Biophysics, Bioinformatics and Biocomplexity &#x02018;L. Galvani&#x02019; (CIG), Bologna, Italy</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Institute of Biochemistry, Medical Faculty Charit&#x000e9;, Berlin, Germany</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Department of Hematology and Oncology, Section of Anatomic Pathology, University of Bologna and Bellaria Hospital, Bologna, Italy</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Department of Medical Sciences and IRCAD (Interdisciplinary Research Center of Autoimmune Diseases), University of Eastern Piedmont, Novara, Italy</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Department of Biopathology &#x00026; Biomedical Methodologies, University of Palermo, Palermo, Italy</addr-line></aff><aff id="aff7"><label>7</label><addr-line>Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy</addr-line></aff><aff id="aff8"><label>8</label><addr-line>Clinica Neurologica, Ospedale Maggiore della Carit&#x000e0;, Novara, Italy</addr-line></aff><aff id="aff9"><label>9</label><addr-line>U.O. Neurologia Fondazione, Istituto San Raffaele &#x0201c;G.Giglio&#x0201d; di Cefal&#x000f9;, Cefal&#x000f9; (PA), Italy</addr-line></aff><aff id="aff10"><label>10</label><addr-line>Department of Neurological Sciences, University of Milan, IRCCS Fondazione Ospedale Maggiore Policlinico, Milan, Italy</addr-line></aff><aff id="aff11"><label>11</label><addr-line>Institute of Experimental Neurology (INSPE), and Department of Neurology, San Raffaele Scientific Institute, Milan, Italy</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Kleinschnitz</surname><given-names>Christoph</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Julius-Maximilians-Universit&#x000e4;t W&#x000fc;rzburg, Germany</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>michele.mishto@charite.de</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: MM US PMK CF. Performed the experiments: MM EB CL FL EC CF FE DG. Analyzed the data: MM KTT AS MPF. Contributed reagents/materials/analysis tools: MG SD BN ML LMEG FMB DG ES MPA CC. Wrote the paper: MM PMK CF.</p></fn></author-notes><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>18</day><month>2</month><year>2010</year></pub-date><volume>5</volume><issue>2</issue><elocation-id>e9287</elocation-id><history><date date-type="received"><day>4</day><month>12</month><year>2009</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2010</year></date></history><permissions><copyright-statement>Mishto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>Albeit several studies pointed out the pivotal role that CD4&#x0002b;T cells have in Multiple Sclerosis, the CD8&#x0002b; T cells involvement in the pathology is still in its early phases of investigation. Proteasome degradation is the key step in the production of MHC class I-restricted epitopes and therefore its activity could be an important element in the activation and regulation of autoreactive CD8&#x0002b; T cells in Multiple Sclerosis.</p></sec><sec><title>Methodology/Principal Findings</title><p>Immunoproteasomes and PA28-&#x003b1;&#x003b2; regulator are present in MS affected brain area and accumulated in plaques. They are expressed in cell types supposed to be involved in MS development such as neurons, endothelial cells, oligodendrocytes, macrophages/macroglia and lymphocytes. Furthermore, in a genetic study on 1262 Italian MS cases and 845 controls we observed that HLA-A&#x0002a;02&#x0002b; female subjects carrying the immunoproteasome LMP2 codon 60HH variant have a reduced risk to develop MS. Accordingly, immunoproteasomes carrying the LMP2 60H allele produce <italic>in vitro</italic> a lower amount of the HLA-A&#x0002a;0201 restricted immunodominant epitope MBP<sub>111&#x02013;119</sub>.</p></sec><sec><title>Conclusion/Significance</title><p>The immunoproteasome LMP2 60HH variant reduces the risk to develop MS amongst Italian HLA-A&#x0002a;02&#x0002b; females. We propose that such an effect is mediated by the altered proteasome-dependent production of a specific MBP epitope presented on the MHC class I. Our observations thereby support the hypothesis of an involvement of immunoproteasome in the MS pathogenesis.</p></sec></abstract><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Multiple Sclerosis (MS) is the most common autoimmune disorder of the central nervous system (CNS). It is characterized by multifocal areas of demyelization (plaques), chronic inflammation and damage to oligodendrocytes and neurons. The cause of MS is still unknown and disease pathways are poorly understood. However, the association of HLA-DRB1&#x0002a;15 and other HLA class I (<italic>e.g.</italic> HLA-A&#x0002a;02 and HLA-A&#x0002a;03) and class II alleles, the presence of autoreactive T lymphocytes together with other inflammatory cells and cytokines in active MS lesions suggest an autoimmune pathogenesis. Accordingly, the experimental autoimmune encephalomyelitis (EAE), a classical mouse model for MS, can be induced by the administration of myelin antigens or CD4&#x0002b; and CD8&#x0002b; T lymphocytes specific for those antigens <xref ref-type="bibr" rid="pone.0009287-Friese1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Giovannoni1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Fugger1">&#x0005b;3&#x0005d;</xref>. On the basis of recent results on EAE, it has been proposed that the first bout of the disease is mediated by CD8&#x0002b; T cells while the first relapse and further disease are mediated by CD4&#x0002b; T cells through different mechanisms such as antigen release and epitope spreading <xref ref-type="bibr" rid="pone.0009287-Friese2">&#x0005b;4&#x0005d;</xref>.</p><p>The antigen bound on Major Histocompatibility Complex class I (MHC-I) and presented to the T cell receptor (TCR) of CD8&#x0002b; T cells, is normally produced by proteasomes. One of the proteasome isoforms, known as immunoproteasome, enhances the generation of specific antigenic epitopes <xref ref-type="bibr" rid="pone.0009287-Kloetzel1">&#x0005b;5&#x0005d;</xref> and its role in neurodegenerative diseases has recently been described <xref ref-type="bibr" rid="pone.0009287-DiazHernandez1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Mishto1">&#x0005b;7&#x0005d;</xref>. Immunoproteasome differs from the constitutive proteasome by the &#x003b2; subunits with catalytic activity &#x0005b;&#x003b2;1, &#x003b2;2, &#x003b2;5 into constitutive proteasome and Low Molecular Mass Polypeptide 2 (LMP2), Multicatalytic Endopeptidase Complex Subunit (MECL-1) and LMP7 into immunoproteasome&#x0005d; <xref ref-type="bibr" rid="pone.0009287-Kloetzel1">&#x0005b;5&#x0005d;</xref>. Immunoproteasome assembly can be induced by IFN-&#x003b3;, which also stimulates the expression of proteasome activator-&#x003b1;&#x003b2; (PA28-&#x003b1;&#x003b2;). This regulatory complex binds to the end of the 20S proteasome core, increasing the cleavage rate in an ATP-independent manner and affecting the quality of protein digestion <xref ref-type="bibr" rid="pone.0009287-Kloetzel1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Mishto2">&#x0005b;8&#x0005d;</xref>. Moreover, a role for immunoproteasomes has been suggested in some autoimmune diseases such as ankylosing spondylitis and psoriasis because of the association of a polymorphism of its LMP2 subunit to the those pathologies <xref ref-type="bibr" rid="pone.0009287-Kramer1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Maksymowych1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-VargasAlarcon1">&#x0005b;11&#x0005d;</xref>. This particular polymorphism is a non-conservative nucleotide base pair change at amino acid position 60 (in exon 3), resulting in two alleles, arginine (R) or histidine (H). It modifies the susceptibility of peripheral blood mononuclear cells to TNF-&#x003b1; induced-apoptosis in elderly donors <xref ref-type="bibr" rid="pone.0009287-Mishto3">&#x0005b;12&#x0005d;</xref>, as well as the proteasome activity in brain protein extracts from Alzheimer patients and non-demented elderly <xref ref-type="bibr" rid="pone.0009287-Mishto1">&#x0005b;7&#x0005d;</xref>.</p><p>In this study, we investigated the presence of immunoproteasome in the CNS of MS patients and whether its LMP2 polymorphism might be involved in MS onset. The data we obtained indicates that immunoproteasomes and PA28-&#x003b1;&#x003b2; regulator are present in MS CNS and that the LMP2 60HH genotype impinges upon MS, likely in part by reducing the production of a specific HLA-A&#x0002a;02 restricted Myelin Basic Protein epitope (MBP<sub>111&#x02013;119</sub>) implicated in MS pathology <xref ref-type="bibr" rid="pone.0009287-Jurewicz1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Tsuchida1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Zang1">&#x0005b;15&#x0005d;</xref> as shown in <italic>in vitro</italic> assays and in the presence of PA28-&#x003b1;&#x003b2;. Furthermore, these results add further evidences on the complex role of HLA-A&#x0002a;02 allele in the pathogenesis of this disease.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and Methods</title><p>The Ethics Committees of the University of Bologna, Florence, Empoli, Milan and Eastern Piedmont approved this study. An informed written consent to participate in this study was obtained from all participants.</p><sec id="s2a"><title>Patients and Controls</title><p>Two independent MS populations were genotyped and compared to a common Italian control population. The samples consisted of: i. 694 MS patients (mean age: 38.8&#x0002b;/&#x02212;11.7 years) for the first MS population consecutively referred to the Department of Neurology of the University of Florence, the Hospital of Empoli, the University of Eastern Piedmont (Novara); ii. 568 MS patients (mean age: 43.4&#x0002b;/&#x02212;12.4 years) for the second MS population referred to the Institute of Experimental Neurology and Department of Neurology - San Raffaele Scientific Institute (Milan) and the IRCCS Fondazione Ospedale Maggiore Policlinico (Milan). The two independent samples were compared to a population of 845 age- and area-matched controls (mean age: 37.8&#x0002b;/&#x02212;12.9 years) and then grouped providing a total MS sample of 1262 patients (mean age: 41.6&#x0002b;/&#x02212;12.3). Inclusion criteria were a definite diagnosis of MS <xref ref-type="bibr" rid="pone.0009287-McDonald1">&#x0005b;16&#x0005d;</xref>, age &#x02265;18 years and written informed consent. All controls were carefully assessed to exclude diagnosis of inflammatory disorders. DNA was extracted from peripheral blood of controls and MS patients as previously described <xref ref-type="bibr" rid="pone.0009287-Mishto3">&#x0005b;12&#x0005d;</xref>.</p></sec><sec id="s2b"><title>Materials and Chemicals</title><p>Fetal calf serum and RPMI 1640 medium were from Biowhittaker (Belgium). The restriction enzymes were from MBI Fermentas (Latvia). The peptide MBP<sub>102&#x02013;109</sub> (seq. 102&#x02013;129 of the human classical Myelin Basic Protein (MBP) isoform 5) has the following sequence: PSQGKGRGL<bold>SLSRFSWGA</bold>EGQRPGFGYG-CONH2 term. In bold the sequence of the analyzed epitope MBP<sub>111&#x02013;119,</sub> HLA-A&#x0002a;0201 restricted, detected in MS patient blood and believed to be involved in MS <xref ref-type="bibr" rid="pone.0009287-Jurewicz1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Tsuchida1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Zang1">&#x0005b;15&#x0005d;</xref>. The epitope (ELA)-MART1<sub>26&#x02013;35</sub> used in comparison with MBP<sub>111&#x02013;119</sub> has the following sequence: ELAGIGILTV-COOH term <xref ref-type="bibr" rid="pone.0009287-Valmori1">&#x0005b;17&#x0005d;</xref>. All peptides have been synthesized by Dr. P. Henklein (Institute of Biochemistry, Medical Faculty Charit&#x000e9;, Berlin, Germany).</p></sec><sec id="s2c"><title>Immunohistochemistry (IHC)</title><p>In the present study we described &#x0201c;immunoproteasomes&#x0201d; as any iso-form of proteasome that contains immunosubunits, thereby also including intermediate-types <xref ref-type="bibr" rid="pone.0009287-Klare1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Kloss1">&#x0005b;19&#x0005d;</xref>. IHC assays were performed on parietal lobes and rostral medulla (with MS plaques) of three MS patients (2 males, 37 and 49 years old; 1 female, 49 years old) and two young controls (females, 21 and 42 years old), provided by the Department of Hematology and Oncology, &#x0201c;L. and A. Seragnoli&#x0201d; Section of Anatomic Pathology, University of Bologna at Bellaria Hospital, Bologna, Italy. The IHC showed in <xref ref-type="fig" rid="pone-0009287-g001">Figure 1</xref>, <xref ref-type="fig" rid="pone-0009287-g002">2</xref> and <xref ref-type="fig" rid="pone-0009287-g003">3</xref> referred to autopsy samples derived from MS and control donors (respectively 49 and 42 years old) died by lung embolus and gastric hemorrhage, respectively. Both autopsies were carried out after 24 h from the death and almost all brain was included for histological examination and diagnostic definition of the disease. For the present study we selected brain areas carrying the histopathological features of active chronic plaques. These plaques, included for our immunohistochemical examination, were characterized by area of myelin reduction containing numerous macrophages with clear and foamy cytoplasm, positive with acid periodic Schiff staining (PAS) after diastase digestion. The same macrophages contained myelin degradation products, which reacted with the Luxol Fast Blue (LFB) staining and were mainly located in the peripheral part of the plaque as previously described <xref ref-type="bibr" rid="pone.0009287-Frischer1">&#x0005b;20&#x0005d;</xref>. The presence of macrophages and microglial cells has been evidenced by anti-CD68 immunostaining. In addition small venules, surrounded by mature lymphocytes, were present within the plaques. The lymphocyte population, characterized at the time of the diagnosis, consisted mainly of mature T cells, CD8 positive. The other MS and controls samples were biopsies obtained during surgery to investigate the presence of possible cancers. In the brain of subjects classified as MS patients characteristic MS lesions, were identified, instead of cancer markers; in contrast, neither cancer nor MS plaques were observed in the control sample.</p><fig id="pone-0009287-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009287.g001</object-id><label>Figure 1</label><caption><title>LMP2 subunit and PA28-&#x003b1;&#x003b2; are expressed in CNS cortex and white matter of MS but not of young controls.</title><p>Example of cortex (A, C) and plaque into white matter (B, D) of MS parietal lobe, stained with anti-LMP2 (A, B) and anti-PA28-&#x003b1; (C, D) Abs are shown. Different cell types, positive to the staining, are marked as following: 1. neurons; 2. luminal endothelial cells; 3. astrocytes; 4. oligodendrocytes (putative). Example of a parietal lobe cortex (E, G) and white matter (F, H) of young control stained with anti-LMP2 (E, F) and anti-PA28-&#x003b1; (G, H) Abs, which bind only luminal endothelial cells (see arrow). In (I) and (L) example of a parietal lobe white matter of a MS patient stained with anti-&#x003b2;1 and anti-&#x003b1;4 Abs are shown, respectively. As expected, all cells are positive to both stainings. The representative samples here reported derived from gender- and age-matched MS and control samples. A, C, D, F, G, H, I scale bars&#x0200a;&#x0003d;&#x0200a;50 &#x000b5;m; B, E, L scale bars&#x0200a;&#x0003d;&#x0200a;25 &#x000b5;m.</p></caption><graphic xlink:href="pone.0009287.g001"/></fig><fig id="pone-0009287-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009287.g002</object-id><label>Figure 2</label><caption><title>LMP2 subunit is accumulated in MS plaques.</title><p>(A) Cortex, white matter and plaque of MS parietal lobe stained with anti-LMP2 Ab; an increase of cells expressing LMP2 in the plaque emerges. (B) In control parietal lobe, cortex and white matter marked with anti-LMP2 Ab show a detectable staining only in luminal endothelial cells. The labeling with anti-&#x003b2;1 Ab of the same MS (C) and control (D) brain area do not show any difference neither between MS and control nor between grey and white matters. (E) Rostral medulla, with MS plaque into inferior olivar nucleus (arrow), stained with anti-LMP2 Ab, which mainly binds the MS plaque. The representative samples here reported derived from gender- and age-matched MS and control samples. A-D scale bars&#x0200a;&#x0003d;&#x0200a;300 &#x000b5;m; E scale bar&#x0200a;&#x0003d;&#x0200a;3 mm.</p></caption><graphic xlink:href="pone.0009287.g002"/></fig><fig id="pone-0009287-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009287.g003</object-id><label>Figure 3</label><caption><title>LMP2 subunit and PA28-&#x003b1;&#x003b2; are expressed in different cell types, including oligodendrocytes, macrophages and microglial cells in MS brains.</title><p>A) To discriminate among oligodendrocytes and lymphocytes, we performed a double staining with anti-LMP2 (brown) and anti- CD45RB (red) Abs in parietal lobe of MS brains. Many oligodendrocytes (only brown stained; marked with 1) and lymphocytes (brown and red stained; marked with 2) are visible. B) Oligodendrocyte identification was confirmed by staining the same area with anti-LMP2 (brown) and anti-Olig2 (blue) Abs and observing a clear labeling of oligodendrocytes for both Olig2 and LMP2 (marked by arrow). C) Oligodendrocytes (marked by arrow) express also PA28-&#x003b1;&#x003b2; as emerged by the double staining of MS parietal lobe with anti-PA28-&#x003b1; (blue) and anti-Olig2 (brown). A double staining for LMP2 (brown) and CD68 (red) verified that microglia/macrophages (marked with arrows) express the immunoproteasome subunit in parenchyma (D) and perivascular (E) parietal lobe of MS brains. F) Microglia/macrophages (marked with arrows) also express PA28-&#x003b1;&#x003b2; as revealed by the double staining with anti-PA28-&#x003b1; (blue) and anti-CD68 (brown) Abs. A, E scale bars&#x0200a;&#x0003d;&#x0200a;25 &#x000b5;m; B, C scale bars&#x0200a;&#x0003d;&#x0200a;10 &#x000b5;m. D, F scale bars&#x0200a;&#x0003d;&#x0200a;50 &#x000b5;m.</p></caption><graphic xlink:href="pone.0009287.g003"/></fig><p>Immunostaining was performed as previously described <xref ref-type="bibr" rid="pone.0009287-Mishto1">&#x0005b;7&#x0005d;</xref> adopting a dilution 1&#x02236;100 of LMP2 and 1&#x02236;50 of LMP7 antibodies (Abs) (Affinity- Biomol International, Plymouth Meeting, PA, USA). In addition, mouse monoclonal Ab to human 20S proteasome subunit &#x003b1;4 (diluted 1&#x02236;25; Affinity- Biomol International, Plymouth Meeting, PA, USA) and rabbit polyclonal PA28&#x003b1; (diluted 1&#x02236;50; Affinity- Biomol International, Plymouth Meeting, PA, USA) were used. Double stainings with Abs anti-LMP2 and anti-CD68 (Dako, Carpintera, CA, USA, diluted 1&#x02236;150, clone KP1 that recognizes macrophages/microglial cells), anti LMP2 and anti-CD45RB (Dako, Carpintera, CA, USA, diluted 1&#x02236;600; Abs from clones 2B11 &#x0002b; PD7\26 that recognizes antigens clustered as CD45RB specific for mature lymphocytes) were performed to identify microglia/macrophages or to distinguish between oligodendrocytes and lymphocytes. In addition, oligodendrocytes identification was also carried out by double immunostaining with anti-LMP2 and anti-Olig2 (Chemicon, Billerica, MA, USA; dilution 1&#x02236;300; polyclonal rabbit that recognizes the transcription factor Olig2 <xref ref-type="bibr" rid="pone.0009287-Karadottir1">&#x0005b;21&#x0005d;</xref> specific for oligodendrocytes) as well as anti-PA28-&#x003b1; and anti-Olig2. Double immunostainings with anti-LMP2 and anti-CD45RB or anti-CD68 were performed according to the following procedure: after biotinylated goat anti-polyvalent, two types of streptavidin were used, the first conjugated with peroxidase (Lab VISION Ultra vision Large Detection System Anti-polyvalent HRP, Fremont, CA, USA) and the second with alkaline phosphatase (DakoCytomation ChemMate Detectin Kit, Alkaline Phosphatase/RED, Rabbit/Mouse K5005, Carpintera, CA, USA) and two different chromogens: 3,3&#x02032;-diaminobenzidine (Dako Liquid DAB-substrate- Chromogen system K3468, Carpintera, CA, USA) for streptavidin peroxidase and the fast red Working solution (CHROM) (Dako, Carpintera, CA, USA) for alkaline phosphatase. Double immunostainings with anti-LMP2/anti-Olig2 and with anti-PA28-&#x003b1;/anti-Olig2 were performed following the previous procedure but employing as second chromogen Perma\Blue AP Chromogen (Diagnostic Biosystems, Pleasonton, CA, USA) for alkaline phosphatase.</p></sec><sec id="s2d"><title>Cell Cultures</title><p>Lymphoblastoid cell lines (LcLs) are human B lymphocytes immortalized with Epstein Barr virus (EBV) which mainly express immunoproteasomes, as previously reported <xref ref-type="bibr" rid="pone.0009287-Mishto4">&#x0005b;22&#x0005d;</xref>. T2 cell line is a human T cell leukemia/B cell line hybrid defective in TAP1/TAP2 and LMP2/LMP7 subunits and expressing the HLA-A&#x0002a;0201 allele <xref ref-type="bibr" rid="pone.0009287-Kuckelkorn1">&#x0005b;23&#x0005d;</xref>. LcLs and T2 cell lines were cultured in RPMI1640 medium supplemented with 10&#x00025; FCS.</p></sec><sec id="s2e"><title>Isolation of DNA from LcLs and Genotyping of Patients, Controls and LcLs</title><p>DNA from LcLs was collected from 15&#x0002a;10<sup>6</sup> cells using TRIZOL reagent (Life Technologies, Paisley, UK) as previously reported <xref ref-type="bibr" rid="pone.0009287-Mishto4">&#x0005b;22&#x0005d;</xref>. DNA from donors for the genetic study was obtained from peripheral blood and genotyped for LMP2 codon 60 polymorphism, HLA-A&#x0002a;02 and HLA-DRB1&#x0002a;15 alleles. LMP2 genotyping was performed using standard PCR methods and DNA enzymatic digestions as previously described <xref ref-type="bibr" rid="pone.0009287-Mishto3">&#x0005b;12&#x0005d;</xref>. Genotyping for HLA-A&#x0002a;02 and HLA-DRB1&#x0002a;15 was performed by PCR-SSP analysis; as internal controls, regions of 330 bp of &#x003b2;2 microglobulin and 520 bp of MOG (Myelin Oligodendrocyte Glycoprotein) promoter were amplified.</p></sec><sec id="s2f"><title>20S Proteasome and PA28-&#x003b1;&#x003b2; Purifications</title><p>PA28-&#x003b1;&#x003b2; and 20S proteasomes were purified from 9 LcLs (genotyped for LMP2 codon 60 polymorphism) as previously described <xref ref-type="bibr" rid="pone.0009287-Mishto2">&#x0005b;8&#x0005d;</xref>. The final step of the PA28-&#x003b1;&#x003b2; purification was the fractioning by chromatography on a phenylsepharose column of pooled material obtained from all the LCLs. Isolated PA28-&#x003b1;&#x003b2; stimulated proteasomal activity on Suc-LLVY-MCA substrate up to five-fold and no activity was observed in controls without 20S proteasome testifying the absence of protease contamination in the PA28-&#x003b1;&#x003b2; preparation. Final purified PA28-&#x003b1;&#x003b2; was tested on SDS-PAGE and stained with Comassie-Blue.</p></sec><sec id="s2g"><title>Digestion of Long Substrates, Epitope Detection and Their Quantification by Mass Spectrometry</title><p>The digestion of the synthetic peptide MBP<sub>102&#x02013;129</sub> by purified 20S proteasomes&#x0002b;/&#x02212;PA28-&#x003b1;&#x003b2; was performed in Hepes buffer in different condition. In particular, to examine the effects of LMP2 polymorphism on MBP<sub>102&#x02013;129</sub> degradation, 20 &#x000b5;g MBP<sub>102&#x02013;129</sub> peptide was dissolved in 100 &#x000b5;l buffer-1 (20 mM Hepes pH 7.8, 2 mM MgAcetate, 1 mM dithiothreitol) and incubated with 0.5 &#x000b5;g 20S proteasome or dissolved in 100 &#x000b5;l buffer-2 (20 mM Hepes pH 7.8, 1 mM dithiothreitol) and incubated with 0.25 &#x000b5;g 20S proteasome&#x0002b;3 &#x000b5;l PA28-&#x003b1;&#x003b2;. To examine the effects of PA28-&#x003b1;&#x003b2; on MBP<sub>102&#x02013;129</sub> degradation, 20 &#x000b5;g MBP<sub>102&#x02013;129</sub> was incubated with 0.25 &#x000b5;g 20S proteasome&#x0002b;/&#x02212;3 &#x000b5;l PA28-&#x003b1;&#x003b2;. Digestions were stopped by acidic inactivation and samples frozen. Samples were analyzed by mass spectrometry as previously described <xref ref-type="bibr" rid="pone.0009287-Mishto4">&#x0005b;22&#x0005d;</xref>. Briefly, they were quantified by C18 reversed phase HPLC (HP1100, Agilent) followed by an ESI-MS analyses performed online with a LCQ ion trap mass spectrometer (Thermo Fisher). Peptides were identified by their molecular masses calculated from the m/z peaks of the single or multiple charged ions and were confirmed by tandem mass spectrometry sequencing analyses. To test the absence of protease contamination in the PA28-&#x003b1;&#x003b2; preparation, the substrate MBP<sub>102&#x02013;129</sub> was digested in the usual digestion solution without 20S proteasomes for 60 mins and no detectable degradation of the substrate was observed. Moreover, when 20S proteasomes were inhibited by MG132 (final concentration of 5 &#x000b5;M) no substrate degradation was observed, confirming the absence of other proteases in the 20S proteasome preparation. The impact of LMP2 R60H polymorphism on MBP<sub>102&#x02013;129</sub> degradation was tested computing the degradation rate constant (K<sub>1</sub>) in a reaction of first order. The Specific Production (SP) of the fragments 10&#x02013;18 (MBP<sub>111&#x02013;119</sub> epitope) by 20S immunoproteasomes &#x0002b;/&#x02212; PA28-&#x003b1;&#x003b2; carrying different LMP2 60 variants was computed as following: (fragment signal)/(signal of substrate degraded) multiplied for a factor of 1000 (to facilitate the comparison by readers). The SP provided <italic>de facto</italic> an estimation of the epitope produced per digested substrate based on the mass spectrometry signal. Only peptide signals in samples with similar substrate degradation and less than 50&#x00025; of substrate consumption were compared to minimize errors during peptide quantification and the re-entry of products in the proteasome core, consequently obtaining epitope SP by 20S proteasomes carrying different LMP2 codon 60 variants at different percentage of substrate degraded (&#x0003c;25&#x00025;, between 25&#x00025; and 35&#x00025;, between 35&#x00025; and 50&#x00025;).</p></sec><sec id="s2h"><title>Flow Cytometric Analysis of the Binding Affinity of Epitopes-HLA-A&#x0002a;0201</title><p>T2 cells (3&#x000d7;10<sup>5</sup> cells/ml) were incubated with various concentrations of peptides MBP<sub>111&#x02013;119</sub> or (ELA)-MART1<sub>26&#x02013;35</sub> (100&#x02013;0,1 &#x000b5;g/ml) in serum-free RPMI 1640 medium for 16h. Afterwards, cells were washed and incubated with anti-HLA-A&#x0002a;02 Ab-FITC and the HLA-A&#x0002a;02 stabilization on cell surface by bound epitope was measured by flow cytometer FACScalibur. Net fluorescence reported in <xref ref-type="supplementary-material" rid="pone.0009287.s001">Fig. S1</xref> was computed by subtraction of fluorescence detected in control samples (with Ab and without peptides).</p></sec><sec id="s2i"><title>Statistical Analyses</title><p>Statistical analyses of <italic>in vitro</italic> digestion data were performed using the tests of Monte Carlo Anova to evaluate the effect of LMP2 R60H polymorphism, <italic>t</italic>-student for independent samples to evaluate the effect of LMP2 60H allele and Mann-Whitney test to evaluate the effect of PA28-&#x003b1;&#x003b2;. To compare mass spectrometry values obtained from different experiments, mass spectrometry signals were standardized within each degradation set and then compared. In each data set, homogeneity of variance was checked by Levene's test. Comparisons of genetic distributions were assessed by Monte Carlo Pearson &#x003c7;<sup>2</sup> test. Investigation of MS onset age was performed with Monte Carlo Anova test. Hardy Weinberg equilibrium was tested using the Pearson &#x003c7;<sup>2</sup> test. p&#x0003c;0.05 was considered statistically significant. All the analyses were implemented using SPSS software. Pair-wise linkage disequilibrium was evaluated by two linkage disequilibrium parameters, Lewontin's D2 <xref ref-type="bibr" rid="pone.0009287-Lewontin1">&#x0005b;24&#x0005d;</xref> and r<sup>2</sup><xref ref-type="bibr" rid="pone.0009287-Devlin1">&#x0005b;25&#x0005d;</xref>, which were both calculated in haploview (<ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/mpg/haploview/">http://www.broad.mit.edu/mpg/haploview/</ext-link>) <xref ref-type="bibr" rid="pone.0009287-Barrett1">&#x0005b;26&#x0005d;</xref>.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Immunoproteasome Subunits Are Present in the CNS of MS Patients (and Concentrated in MS Plaques) but Not of Young Controls</title><p>Although the mechanisms of MS are still largely unknown, some cell types seem to be involved in the pathogenesis of this disease. Therefore, we first investigated if immunoproteasome and PA28-&#x003b1;&#x003b2; subunits are expressed in MS CNS and in which cells. Grey and white matters of parietal lobe from three MS patients and two young controls were initially stained with Abs specific for constitutive proteasome (&#x003b2;1), immunoproteasome (LMP2 &#x00026; LMP7) and PA28-&#x003b1; subunits. In the cortex (<xref ref-type="fig" rid="pone-0009287-g001">Fig. 1A</xref>) and in the plaques of the white matter (<xref ref-type="fig" rid="pone-0009287-g001">Fig. 1B</xref>) of MS patients, LMP2 was detected in different cell types. Similar results were obtained staining the same area with Abs anti-LMP7 (data not shown) and anti-PA28-&#x003b1; (<xref ref-type="fig" rid="pone-0009287-g001">Fig. 1C, D</xref>). In contrast, all stainings were negative both in cortex and white matter of the same CNS area of young controls except for luminal endothelial cells, which were positive to anti-LMP2 (<xref ref-type="fig" rid="pone-0009287-g001">Fig. 1E, F</xref>) and anti-PA28-&#x003b1; (<xref ref-type="fig" rid="pone-0009287-g001">Fig. 1G, H</xref>) Abs. As expected, proteasome &#x003b2;1 and &#x003b1;4 subunits were expressed in all cell types, both in MS patients (<xref ref-type="fig" rid="pone-0009287-g001">Fig. 1I &#x00026; L</xref>, respectively) and in young controls (data not shown).</p><p>Moreover, LMP2 expression was predominant in MS plaques (<xref ref-type="fig" rid="pone-0009287-g002">Fig. 2A</xref>) compared to pre-plaque white matter and cortex while in the same CNS area of control only luminal endothelial cells were stained (<xref ref-type="fig" rid="pone-0009287-g002">Fig. 2B</xref>). Otherwise, &#x003b2;1 subunit was equally distributed in grey and white matter of MS (<xref ref-type="fig" rid="pone-0009287-g002">Fig. 2C</xref>) and control (<xref ref-type="fig" rid="pone-0009287-g002">Fig. 2D</xref>). Such an accumulation of the immunoproteasome subunit in the plaque area was even more evident in the rostral medulla of a MS patient stained with Ab anti-LMP2, which mainly spotted the plaque into inferior olivar nucleus, whereas other areas were weakly stained (<xref ref-type="fig" rid="pone-0009287-g002">Fig. 2E</xref>).</p></sec><sec id="s3b"><title>Immunoproteasome and PA28-&#x003b1;&#x003b2; Subunits Are Expressed in Different Cell Types in the CNS of MS Patients</title><p>In the CNS areas affected by the disease, LMP2 and PA28-&#x003b1;&#x003b2; were expressed in different cell types such as neurons, luminal endothelial cells, astrocytes (<xref ref-type="fig" rid="pone-0009287-g001">Fig. 1A, C</xref>) and, in white matter plaques, also in (putative) oligodendrocytes (<xref ref-type="fig" rid="pone-0009287-g001">Fig. 1B, D</xref>). To verify that oligodendrocytes express LMP2 &#x00026; PA28-&#x003b1;&#x003b2; and to distinguish them from lymphocytes, we performed a double IHC staining of MS parietal lobe slices using Abs anti-LMP2 (or anti-PA28-&#x003b1;) and anti-CD45RB (marker of mature lymphocytes). As shown in <xref ref-type="fig" rid="pone-0009287-g003">Figure 3A</xref>, lymphocytes present in white matter were positive to anti-LMP2 and anti-CD45RB staining. In addition, small rounded nuclei, positive to anti-LMP2 and negative to anti-CD45RB Abs, corresponding to oligodendrocytes, were present. This result was further confirmed by anti-LMP2 and anti-Olig2 labeling of the same MS brain area where oligodendrocytes were positive to both LMP2 and the oligodendrocytes transcription factor Olig2, while other cells were only stained for LMP2 (<xref ref-type="fig" rid="pone-0009287-g003">Fig. 3B</xref>). Similarly, PA28-&#x003b1;&#x003b2; was detected in oligodendrocytes, positive to both anti-PA28-&#x003b1; and anti-Olig2 Abs (<xref ref-type="fig" rid="pone-0009287-g003">Fig. 3C</xref>).</p><p>Furthermore, we performed IHC double staining with Abs anti-CD68 (marker of microglial cells and macrophages) and anti-LMP2 (or anti-PA28-&#x003b1;&#x003b2;) in MS parietal lobe. Microglial cells and macrophages expressed both CD68 and LMP2 (<xref ref-type="fig" rid="pone-0009287-g003">Fig. 3D, E</xref>) as well as CD68 and PA28-&#x003b1;&#x003b2; (<xref ref-type="fig" rid="pone-0009287-g003">Fig. 3F</xref>), proving that immunoproteasomes were present in these cell types also <italic>in vivo</italic> and thus extending the <italic>in vitro</italic> observations of Stohwasser and co-workers <xref ref-type="bibr" rid="pone.0009287-Stohwasser1">&#x0005b;27&#x0005d;</xref>.</p></sec><sec id="s3c"><title>The Immunodominant Epitope MBP<sub>111&#x02013;119</sub> Is Produced In Vitro by Immunoproteasomes and PA28-&#x003b1;&#x003b2; Increases the Efficiency of Its Production</title><p>To test the involvement of immunoproteasome and its LMP2 R60H polymorphism in MS we investigated one of the major immunodominant self-epitopes detected in MS patient blood <xref ref-type="bibr" rid="pone.0009287-Jurewicz1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Tsuchida1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Zang1">&#x0005b;15&#x0005d;</xref>, <italic>i.e.</italic> MBP<sub>111&#x02013;119</sub> (HLA-A&#x0002a;0201-restricted). This epitope bound the MHC&#x02013;I (HLA-A&#x0002a;0201) with a relative good affinity (<xref ref-type="supplementary-material" rid="pone.0009287.s001">Fig. S1</xref>) and is present in both the classic and golli MBP. This an important aspect because, as demonstrated in EAE, these two MBP families can play different roles in central and peripheral tolerance towards MBP-reactive CD8&#x0002b; T cells <xref ref-type="bibr" rid="pone.0009287-Perchellet1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Perchellet2">&#x0005b;29&#x0005d;</xref>.</p><p>The 28mer peptide (MBP<sub>102&#x02013;129</sub>), which contains the epitope MBP<sub>111&#x02013;119</sub>, was digested <italic>in vitro</italic> by 20S immunoproteasomes in presence or absence of PA28-&#x003b1;&#x003b2;, which is strongly implicated in MHC-I antigen presentation by increasing the production of some epitopes <xref ref-type="bibr" rid="pone.0009287-Strehl1">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-TextorisTaube1">&#x0005b;31&#x0005d;</xref>.</p><p>We observed that this regulatory complex increased the degradation rate of MBP<sub>102&#x02013;129</sub> (<xref ref-type="fig" rid="pone-0009287-g004">Fig. 4A</xref>) as well as the MBP<sub>111&#x02013;119</sub> specific production (SP) (M-W U&#x0200a;&#x0003d;&#x0200a;0; p&#x0200a;&#x0003d;&#x0200a;0.002), as also indirectly confirmed by the concomitant higher SP of the flanking peptide 1&#x02013;9 ( M-W U&#x0200a;&#x0003d;&#x0200a;0; p&#x0200a;&#x0003d;&#x0200a;0.002) (<xref ref-type="fig" rid="pone-0009287-g004">Fig. 4B</xref>).</p><fig id="pone-0009287-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009287.g004</object-id><label>Figure 4</label><caption><title>20S immunoproteasomes (&#x0002b; PA28-&#x003b1;&#x003b2;) carrying LMP2 60H allele have a lower SP of the MBP<sub>111&#x02013;119</sub> epitope.</title><p>(A) Chart shows the time-dependent kinetics of MBP<sub>102&#x02013;129</sub> degradation increased in presence of PA28<bold>-</bold>&#x003b1;&#x003b2;. (B) Specific production (SP) &#x0005b;expressed as: (peptide signal/consumed substrate signal)&#x0002a;1000&#x0005d; of the MBP<sub>111&#x02013;119</sub> epitope (peptide 10&#x02013;18 of MBP<sub>102&#x02013;129</sub>) and of the two flanking peptides 1&#x02013;9 and 19&#x02013;28 in absence or presence of PA28<bold>-</bold>&#x003b1;&#x003b2;. The values are the average of the SPs measured at different time points. (C) In presence of PA28-&#x003b1;&#x003b2;, H-carrier 20S immunoproteasomes have a significant lower epitope SP in all three selected ranges of substrate consumption. No significant difference emerged, on the contrary, in absence of PA28-&#x003b1;&#x003b2; (D). (E) The similar rate constant K<sub>1</sub> of MBP<sub>102&#x02013;129</sub> digestion by 20S immunoproteasomes (in presence of PA28-&#x003b1;&#x003b2;) carrying the three LMP2 codon 60 variants. All values are given as mean<bold>&#x0002b;</bold>S.E.M. Statistical significance (p&#x0003c;0.05) is marked with &#x0002a;.</p></caption><graphic xlink:href="pone.0009287.g004"/></fig></sec><sec id="s3d"><title>LMP2 R60H Polymorphism Influences the Efficiency of MBP<sub>111&#x02013;119</sub> Production by 20S Immunoproteasomes in the Presence of PA28-&#x003b1;&#x003b2;</title><p>To investigate the impact of the LMP2 R60H polymorphism on the production of the epitope MBP<sub>111&#x02013;119</sub>, we performed <italic>in vitro</italic> digestions of the substrate MBP<sub>102&#x02013;129</sub> by 20S immunoproteasomes (with or without PA28-&#x003b1;&#x003b2;) purified from 9 LcLs carrying different LMP2 R60H variants. The epitope SP in the presence of PA28-&#x003b1;&#x003b2; was associated with the LMP2 R60H polymorphism (F&#x0200a;&#x0003d;&#x0200a;15.49; p&#x0200a;&#x0003d;&#x0200a;0.004) and was significantly lower (a decrease of 28.8&#x00025;) in LMP2 H-carriers (t&#x0200a;&#x0003d;&#x0200a;8.08; p&#x0003c;0.001) when less than the 25&#x00025; of the substrate was consumed (<xref ref-type="fig" rid="pone-0009287-g004">Fig. 4C</xref>). Such a result was confirmed by a decreased epitope SP of 28.5&#x00025; and 21.72&#x00025; when 25&#x02013;35&#x00025; (t&#x0200a;&#x0003d;&#x0200a;2.97; p&#x0200a;&#x0003d;&#x0200a;0.021) or 35&#x02013;50&#x00025; (t&#x0200a;&#x0003d;&#x0200a;4.75; p&#x0200a;&#x0003d;&#x0200a;0.002) of substrate was consumed, respectively. Such an association of the LMP2 R60H polymorphism with the epitope SP was not detected in the absence of PA28-&#x003b1;&#x003b2; (F&#x0200a;&#x0003d;&#x0200a;0.306; p&#x0200a;&#x0003d;&#x0200a;0.747, <italic>e.g.</italic>, with 25&#x02013;35&#x00025; substrate consumed) and, accordingly, it was similar between LMP2 H-carriers and H-not-carriers when less than 25&#x00025; (t&#x0200a;&#x0003d;&#x0200a;&#x02212;0.47; p&#x0200a;&#x0003d;&#x0200a;0.962), 25&#x02013;35&#x00025; (t&#x0200a;&#x0003d;&#x0200a;&#x02212;0.77; p&#x0200a;&#x0003d;&#x0200a;0.462) and 35&#x02013;50&#x00025; (t&#x0200a;&#x0003d;&#x0200a;0.35; p&#x0200a;&#x0003d;&#x0200a;0.744) of the substrate was consumed (<xref ref-type="fig" rid="pone-0009287-g004">Fig. 4D</xref>).</p><p>Although LMP2 polymorphism influenced the epitope SP, it did not impinge upon the MBP<sub>102&#x02013;129</sub> degradation rate either in the absence <xref ref-type="bibr" rid="pone.0009287-Mishto4">&#x0005b;22&#x0005d;</xref> or in the presence of PA28-&#x003b1;&#x003b2; as described by the comparison of the degradation rate constants &#x0039a;<sub>1</sub> (<xref ref-type="fig" rid="pone-0009287-g004">Fig. 4E</xref>) (F&#x0200a;&#x0003d;&#x0200a;0.206; p&#x0200a;&#x0003d;&#x0200a;0.820).</p></sec><sec id="s3e"><title>LMP2 60HH Variant Decreases the Risk to Develop MS in HLA-A&#x0002a;02&#x0002b; Female Population</title><p>As <italic>in vitro</italic> experiments showed that LMP2 60H allele decreases the production of the HLA-A&#x0002a;02-restricted MBP<sub>111-119</sub> epitope we performed a genetic population study to test its possible impact on MS onset. We genotyped two independent samples of 694 and 598 MS patients as well as 845 geographically- and age-matched controls for LMP2 R60H, HLA-A&#x0002a;02 and HLA-DRB1&#x0002a;15 alleles, considering their gender. The impact of an alteration of MBP<sub>111-119</sub> production on MS pathogenesis should be evident in patients able to present such an epitope on HLA-A&#x0002a;02 MHC-I variant. Accordingly, we compared the LMP2 R60H distribution in HLA-A&#x0002a;02 positive MS patients and control subjects. Both MS population showed the same genetic behavior (<xref ref-type="supplementary-material" rid="pone.0009287.s002">Table S1</xref> &#x00026; <xref ref-type="supplementary-material" rid="pone.0009287.s003">S2</xref>), hence we grouped them in a MS Italian population of 1262 patients and compared them to the control sample (<xref ref-type="table" rid="pone-0009287-t001">Table 1</xref>). A significant decrease in LMP2 60HH frequency emerged in female MS patients carrying the HLA-A&#x0002a;02 allele (<italic>e.g.</italic> LMP2 60HH vs RR: p &#x0200a;&#x0003d;&#x0200a; 0.005; OR &#x0200a;&#x0003d;&#x0200a; 0.443; 95&#x00025; CI &#x0200a;&#x0003d;&#x0200a; 0.249 &#x02013; 0.790) (<xref ref-type="table" rid="pone-0009287-t002">Table 2</xref>) but not in HLA-A&#x0002a;02-positive male MS patients (<xref ref-type="table" rid="pone-0009287-t003">Table 3</xref>) nor in HLA-A&#x0002a;02-negative female and male MS patients (data not shown). In female controls LMP2 60H was not in linkage disequilibrium (LD) neither with HLA-DRB1&#x0002a;15 (D&#x02019; &#x0200a;&#x0003d;&#x0200a; 0.02; r<sup>2</sup> &#x0003c; 0.001; p &#x0003e; 0.05) nor with HLA-A&#x0002a;02 (D&#x02019; &#x0200a;&#x0003d;&#x0200a; 0.03; r<sup>2</sup> &#x0200a;&#x0003d;&#x0200a; 0.001; p &#x0003e; 0.05). Both MS and control populations were in Hardy-Weinberg equilibrium for LMP2 codon 60 polymorphism (data not shown). Furthermore, HLA-A&#x0002a;02 allele was a protective factor against MS (p &#x0200a;&#x0003d;&#x0200a; 0.001; OR &#x0200a;&#x0003d;&#x0200a; 0.671; 95&#x00025; CI &#x0200a;&#x0003d;&#x0200a; 0.529 - 0.851) while HLA-DRB1&#x0002a;15 allele was a risk factor (p &#x0003c; 0.001; OR &#x0200a;&#x0003d;&#x0200a; 2.525; 95&#x00025; CI &#x0200a;&#x0003d;&#x0200a; 1.801 - 3.754) (data not shown), as already reported in the Italian population too <xref ref-type="bibr" rid="pone.0009287-Fugger1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Bergamaschi1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Brynedal1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-DAlfonso1">&#x0005b;34&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Pastorino1">&#x0005b;35&#x0005d;</xref>. No effects on the MS onset age exerted by LMP2 polymorphism in HLA-A&#x0002a;02-positive female MS population (<xref ref-type="table" rid="pone-0009287-t004">Table 4</xref>) and by HLA-A&#x0002a;02 in the total MS population was observed (<xref ref-type="table" rid="pone-0009287-t005">Table 5</xref>).</p><table-wrap id="pone-0009287-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009287.t001</object-id><label>Table 1</label><caption><title>Gender distribution in Italian MS and control populations. Values in brackets in distribution column are percentages. The Italian MS population described in this table is the result of sum of two independent Italian MS samples reciprocally in accordance (see also <xref ref-type="supplementary-material" rid="pone.0009287.s002">Tables S1</xref> &#x00026; <xref ref-type="supplementary-material" rid="pone.0009287.s003">S2</xref>).</title></caption><alternatives><graphic id="pone-0009287-t001-1" xlink:href="pone.0009287.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MS (n&#x0200a;&#x0003d;&#x0200a;1262)</td><td align="left" rowspan="1" colspan="1">control (n&#x0200a;&#x0003d;&#x0200a;845)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">male</td><td align="left" rowspan="1" colspan="1">413 (32.7)</td><td align="left" rowspan="1" colspan="1">437 (51.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">female</td><td align="left" rowspan="1" colspan="1">849 (67.3)</td><td align="left" rowspan="1" colspan="1">408 (48.3)</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone-0009287-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009287.t002</object-id><label>Table 2</label><caption><title>LMP2 60HH variant decreases the risk to develop MS in HLA-A&#x0002a;02 carrier female population. Values in brackets in distribution column are percentages. Statistical results are reported for each genetic analysis. The Italian MS female population described in this table is the result of sum of two independent Italian MS samples reciprocally in accordance (see also <xref ref-type="supplementary-material" rid="pone.0009287.s002">Tables S1</xref> &#x00026; <xref ref-type="supplementary-material" rid="pone.0009287.s003">S2</xref>).</title></caption><alternatives><graphic id="pone-0009287-t002-2" xlink:href="pone.0009287.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">MS (n&#x0200a;&#x0003d;&#x0200a;337)</td><td align="left" rowspan="1" colspan="1">control (n&#x0200a;&#x0003d;&#x0200a;202)</td><td align="left" rowspan="1" colspan="1">p</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HH</td><td align="left" rowspan="1" colspan="1">26 (7.7)</td><td align="left" rowspan="1" colspan="1">32 (15.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">RH</td><td align="left" rowspan="1" colspan="1">146 (43.3)</td><td align="left" rowspan="1" colspan="1">80 (39.6)</td><td align="left" rowspan="1" colspan="1">0.013</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">RR</td><td align="left" rowspan="1" colspan="1">165 (49.0)</td><td align="left" rowspan="1" colspan="1">90 (44.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HH vs RR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">0.443 (0.249&#x02013;0.790)</td></tr><tr><td align="left" rowspan="1" colspan="1">HH vs RH</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.006</td><td align="left" rowspan="1" colspan="1">0.445 (0.248&#x02013;0.799)</td></tr><tr><td align="left" rowspan="1" colspan="1">RH vs RR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.981</td><td align="left" rowspan="1" colspan="1">0.995 (0.684&#x02013;1.448)</td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Allele</td><td align="left" rowspan="1" colspan="1">MS (n&#x0200a;&#x0003d;&#x0200a;674)</td><td align="left" rowspan="1" colspan="1">control (n&#x0200a;&#x0003d;&#x0200a;404)</td><td align="left" rowspan="1" colspan="1">p</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">H</td><td align="left" rowspan="1" colspan="1">198 (29.4)</td><td align="left" rowspan="1" colspan="1">144 (35.6)</td><td align="left" rowspan="1" colspan="1">0.032</td><td align="left" rowspan="1" colspan="1">0.840 (0.713&#x02013;0.989)</td></tr><tr><td align="left" rowspan="1" colspan="1">R</td><td align="left" rowspan="1" colspan="1">476 (70.6)</td><td align="left" rowspan="1" colspan="1">260 (64.4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone-0009287-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009287.t003</object-id><label>Table 3</label><caption><title>LMP2 R60H distribution in HLA-A&#x0002a;02 carrier MS and control male populations. Values in brackets in distribution column are percentages. Statistical results are reported for each genetic analysis. The Italian MS male population described in this table is the result of sum of two independent Italian MS samples reciprocally in accordance (see also <xref ref-type="supplementary-material" rid="pone.0009287.s002">Tables S1</xref> &#x00026; <xref ref-type="supplementary-material" rid="pone.0009287.s003">S2</xref>).</title></caption><alternatives><graphic id="pone-0009287-t003-3" xlink:href="pone.0009287.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">MS (n&#x0200a;&#x0003d;&#x0200a;178)</td><td align="left" rowspan="1" colspan="1">control (n&#x0200a;&#x0003d;&#x0200a;194)</td><td align="left" rowspan="1" colspan="1">p</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HH</td><td align="left" rowspan="1" colspan="1">18 (10.1)</td><td align="left" rowspan="1" colspan="1">21 (10.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">RH</td><td align="left" rowspan="1" colspan="1">85 (47.8)</td><td align="left" rowspan="1" colspan="1">88 (45.4)</td><td align="left" rowspan="1" colspan="1">0.281</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">RR</td><td align="left" rowspan="1" colspan="1">75 (42.1)</td><td align="left" rowspan="1" colspan="1">85 (43.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HH vs RR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.728</td><td align="left" rowspan="1" colspan="1">0.868 (0.389&#x02013;1.933)</td></tr><tr><td align="left" rowspan="1" colspan="1">HH vs RH</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.948</td><td align="left" rowspan="1" colspan="1">1.026 (0.468&#x02013;2.248)</td></tr><tr><td align="left" rowspan="1" colspan="1">RH vs RR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.501</td><td align="left" rowspan="1" colspan="1">0.846 (0.518&#x02013;1.379)</td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Allele</td><td align="left" rowspan="1" colspan="1">MS (n&#x0200a;&#x0003d;&#x0200a;356)</td><td align="left" rowspan="1" colspan="1">control (n&#x0200a;&#x0003d;&#x0200a;388)</td><td align="left" rowspan="1" colspan="1">p</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; CI)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">H</td><td align="left" rowspan="1" colspan="1">121 (34.0)</td><td align="left" rowspan="1" colspan="1">130 (33.5)</td><td align="left" rowspan="1" colspan="1">0.579</td><td align="left" rowspan="1" colspan="1">0.908 (0.646&#x02013;1.276)</td></tr><tr><td align="left" rowspan="1" colspan="1">R</td><td align="left" rowspan="1" colspan="1">235 (66.0)</td><td align="left" rowspan="1" colspan="1">258 (66.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone-0009287-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009287.t004</object-id><label>Table 4</label><caption><title>LMP2 R60H polymorphism and MS onset age in HLA-A&#x0002a;02 carrier female MS population. Means and standard deviations (SD) are reported. The Italian HLA-A&#x0002a;02 carrier female MS population described in this table is the result of sum of two independent Italian MS samples reciprocally in accordance (see also <xref ref-type="supplementary-material" rid="pone.0009287.s002">Tables S1</xref> &#x00026; <xref ref-type="supplementary-material" rid="pone.0009287.s003">S2</xref>).</title></caption><alternatives><graphic id="pone-0009287-t004-4" xlink:href="pone.0009287.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">mean (years)</td><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">p</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HH</td><td align="left" rowspan="1" colspan="1">32.61</td><td align="left" rowspan="1" colspan="1">7.65</td><td align="left" rowspan="1" colspan="1">0.329</td></tr><tr><td align="left" rowspan="1" colspan="1">RH</td><td align="left" rowspan="1" colspan="1">29.48</td><td align="left" rowspan="1" colspan="1">9.65</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">RR</td><td align="left" rowspan="1" colspan="1">30.65</td><td align="left" rowspan="1" colspan="1">10.57</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone-0009287-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009287.t005</object-id><label>Table 5</label><caption><title>MS onset age in HLA-A&#x0002a;02 carrier and not-carrier MS populations. Means and standard deviations (SD) are reported. The Italian MS population described in this table is the result of sum of two independent Italian MS samples reciprocally in accordance (see also <xref ref-type="supplementary-material" rid="pone.0009287.s002">Tables S1</xref> &#x00026; <xref ref-type="supplementary-material" rid="pone.0009287.s003">S2</xref>).</title></caption><alternatives><graphic id="pone-0009287-t005-5" xlink:href="pone.0009287.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">HLA-A&#x0002a;</td><td align="left" rowspan="1" colspan="1">mean (years)</td><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">p</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">02 not-carriers</td><td align="left" rowspan="1" colspan="1">31.11</td><td align="left" rowspan="1" colspan="1">10.79</td><td align="left" rowspan="1" colspan="1">0.206</td></tr><tr><td align="left" rowspan="1" colspan="1">02 carriers</td><td align="left" rowspan="1" colspan="1">30.27</td><td align="left" rowspan="1" colspan="1">10.21</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>The observed gender-dependency of the genetic association is consistent with other studies describing a gender dimorphism in cytokine response towards myelin antigens and a hormonal regulation of the immune system in MS <xref ref-type="bibr" rid="pone.0009287-ElEtr1">&#x0005b;36&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Pelfrey1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Moldovan1">&#x0005b;38&#x0005d;</xref>. LMP2 R60H polymorphism association is gender- (male-) dependent in another autoimmune disease, <italic>i.e.</italic> dermal psoriasis <xref ref-type="bibr" rid="pone.0009287-Kramer1">&#x0005b;9&#x0005d;</xref>. The bulk of these indirect observations suggest a connection between LMP2 codon 60 polymorphism, immunoproteasome activity and gender in immunological dysfunctions. Despite the scarcity of experimental evidences we might speculate that the cytokines responses towards MHC-I myelin epitopes (as demonstrated for the MHC-II <xref ref-type="bibr" rid="pone.0009287-Moldovan1">&#x0005b;38&#x0005d;</xref>) is altered by gender, generating a scenario in which the influence of the LMP2 R60H polymorphism on specific myelin epitopes might impinges upon the MS onset only in females. Indeed, the decreased risk of female subjects carrying the HLA-A&#x0002a;02 allele and the LMP2 60HH variant to develop MS might be explained by the impact of the LMP2 polymorphism on the generation of the HLA-A&#x0002a;02-restricted epitope (MBP<sub>111&#x02013;119</sub>) as well of other epitopes not investigated in this study. Indeed, the decreased presentation of this epitope on the MHC-I (HLA-A&#x0002a;02) complex of antigen presenting cells or other cells involved in MS pathways could reduce the probability to disrupt the physiological tolerance (central or peripheral) of MBP-reactive CD8&#x0002b; T cells and/or their cytotoxicity towards oligodendrocytes thereby restraining the MS onset. We showed that the main producers of myelin sheets, <italic>i.e.</italic> the oligodendrocytes, as well as the macrophages/microglial cells, which express PA28-&#x003b1;&#x003b2; <xref ref-type="bibr" rid="pone.0009287-Liu1">&#x0005b;39&#x0005d;</xref> and golli MBP <xref ref-type="bibr" rid="pone.0009287-Papenfuss1">&#x0005b;40&#x0005d;</xref> during EAE, are positive to LMP2 and PA28-&#x003b1;&#x003b2; staining in MS CNS (<xref ref-type="fig" rid="pone-0009287-g003">Fig. 3</xref>). In oligodendrocytes, a decreased presentation mediated by the LMP2 60HH variant of MBP epitopes (<italic>e.g.</italic> MBP<sub>111&#x02013;119</sub>) on HLA-A&#x0002a;02 MHC could attenuate the cytotoxic activity of MBP-reactive CD8&#x0002b; T cells against their main cell targets. In macrophages/microglial cells (<xref ref-type="fig" rid="pone-0009287-g003">Fig. 3</xref>), the lower presentation of these epitopes could restrain a further clonal expansion of self-reactive CD8&#x0002b; T cells, which has been assumed as one of the key steps of MS development <xref ref-type="bibr" rid="pone.0009287-Friese1">&#x0005b;1&#x0005d;</xref>. Taking into account that CNS endothelial cells express immunoproteasomes and PA28-&#x003b1;&#x003b2; (<xref ref-type="fig" rid="pone-0009287-g001">Fig. 1</xref>) as well as they can present MBP in animal models <xref ref-type="bibr" rid="pone.0009287-Bourdoulous1">&#x0005b;41&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Risau1">&#x0005b;42&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Wilcox1">&#x0005b;43&#x0005d;</xref>, the LMP2 60HH-dependent altered expression of the MBP epitopes (<italic>e.g.</italic> MBP<sub>111&#x02013;119</sub>) might also affect the blood-brain barrier (BBB) crossing. Indeed, it has been recently proposed that, after priming, activated CD8&#x0002b; T cells cross the BBB by an antigen-specific interaction with cerebral endothelium <xref ref-type="bibr" rid="pone.0009287-Galea1">&#x0005b;44&#x0005d;</xref>. Thus, endothelial cells carrying HLA-A&#x0002a;02 and LMP2 60HH might lead to a decreased BBB crossing by MBP-reactive CD8&#x0002b; T cells during the early phases of neuroinflammation, affecting MS development. Furthermore, LMP2 R60H polymorphism might influence not only the mechanisms leading to MS that occur in CNS but also the complex balance between central and peripheral tolerance of MBP-restricted CD8&#x0002b; T cells and thereby their pathological activation in peripheral lymph nodes (<italic>e.g.</italic> cervical and lumbal) by dendritic cells <xref ref-type="bibr" rid="pone.0009287-Friese1">&#x0005b;1&#x0005d;</xref>. Indeed, these cells, which express immunoproteasomes and PA28-&#x003b1;&#x003b2; at their mature stage <xref ref-type="bibr" rid="pone.0009287-Macagno1">&#x0005b;45&#x0005d;</xref>, play a key role in the thymic selection and in peripheral activation of MBP-restricted CD8&#x0002b; T cells by the presentation of endogenous MBP on MHC-I <xref ref-type="bibr" rid="pone.0009287-Perchellet1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Perchellet2">&#x0005b;29&#x0005d;</xref>. As consequence, an alteration of the amount of MBP epitopes (<italic>e.g.</italic> MBP<sub>111&#x02013;119</sub>) presented on dendritic cells due to the LMP2 polymorphism might affect the repertoire of MBP-reactive CD8&#x0002b; T cells and, thereby their eventual activation during the early phases of MS onset.</p><p>Our investigation also addresses the complex role that HLA-A&#x0002a;02 appears to have in MS. We observed a decreased risk to develop MS in Italian female population carrying the HLA-A&#x0002a;02 allele, in agreement with other studies <xref ref-type="bibr" rid="pone.0009287-Bergamaschi1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Brynedal1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Silva1">&#x0005b;46&#x0005d;</xref>. Although the mechanisms are still unknown, HLA-A&#x0002a;02 variant in a specific EAE model appeared to increase the negative selection of MBP-reactive CD8&#x0002b; thymocytes and to decrease the responsiveness of MBP-reactive CD8&#x0002b; T cells in periphery <xref ref-type="bibr" rid="pone.0009287-Friese2">&#x0005b;4&#x0005d;</xref>, thereby protecting from EAE. Our results suggest that LMP2 60HH variant impinges upon the likelihood to develop MS but only in HLA-A&#x0002a;02 carriers. Likewise, LMP2 60H allele decreases the <italic>in vitro</italic> generation of the MBP<sub>111&#x02013;119</sub> epitope by immunoproteasomes thereby suggesting that this specific myelin epitope could play a pathogenetic role in MS when presented on HLA-A&#x0002a;02 MHC. Accordingly, several CD8&#x0002b; T cells reactive to HLA-A&#x0002a;02 myelin epitopes have been identified in peripheral blood of MS subjects <xref ref-type="bibr" rid="pone.0009287-Tsuchida1">&#x0005b;14&#x0005d;</xref>. In particular, MBP<sub>111&#x02013;119</sub>&#x02013;reactive CD8&#x0002b; T cells, which are increased three fold in MS patients peripheral blood, are CD45RO&#x0002b; memory T cells secreting TNF-&#x003b1; and IFN-&#x003b3; after epitope challenging and are cytotoxic towards antigen presenting cells and oligodendrocytes, thus supporting the postulate that these CD8&#x0002b; T cells could contribute to the tissue injury in MS <xref ref-type="bibr" rid="pone.0009287-Jurewicz1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Zang1">&#x0005b;15&#x0005d;</xref>.</p><p>In conclusion, our data suggests that the presence of immunoproteasomes in the CNS could be a marker of a pathological scenario involving neuroinflammation (autoimmunity, neurodegeneration but also ageing) <xref ref-type="bibr" rid="pone.0009287-DiazHernandez1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Mishto1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Mishto5">&#x0005b;47&#x0005d;</xref>, therefore putting immunoproteasome forward as potential candidate for future therapeutic approaches <xref ref-type="bibr" rid="pone.0009287-Meuth1">&#x0005b;48&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Mishto6">&#x0005b;49&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Wehenkel1">&#x0005b;50&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Muchamuel1">&#x0005b;51&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009287-Kuhn1">&#x0005b;52&#x0005d;</xref>.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0009287.s001"><label>Figure S1</label><caption><p>MBP<sub>111&#x02013;119</sub> binds the HLA-A&#x0002a;0201 complex with relative good affinity. A) Comparison of the amount of HLA-A&#x0002a;0201 complexes (marked with a FITC-Ab) presented on the outer surface of T2 cells treated with 100 &#x000b5;g/ml MBP<sub>111&#x02013;119</sub> or (ELA)-MART1<sub>26&#x02013;35</sub> epitopes. In particular, signals of T2 cells are reported: i. without FITC-Ab and epitope; ii. without epitopes and with FITC-Ab; iii. with FITC-Ab and MBP<sub>111&#x02013;119</sub> epitope; iv. with FITC-Ab and (ELA)-MART1<sub>26&#x02013;35</sub> epitope. B) The chart shows the binding affinity of the peptides for the MHC class I complexes presented to the outer surface of T2 cells. The net fluorescence is the fluorescence's difference between the cells incubated with and without the epitopes.</p><p>(2.00 MB TIF)</p></caption><media xlink:href="pone.0009287.s001.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0009287.s002"><label>Table S1</label><caption><p>LMP2 60HH, HLA-A&#x0002a;02 and gender frequency in the first investigated Italian MS population (n&#x0200a;&#x0003d;&#x0200a;694) compared to age-matched Italian control population (n&#x0200a;&#x0003d;&#x0200a;845). (A) Gender distribution in MS patients and control populations. (B) LMP2 R60H polymorphism and allele distribution in MS and control HLA-A&#x0002a;02 carrier populations, taking into account the gender. (C) LMP2 R60H polymorphism and MS onset age in HLA-A&#x0002a;02-positive female MS patients. Values in brackets in distribution column are percentages. Statistical results are reported for each genetic analysis.</p><p>(0.14 MB DOC)</p></caption><media xlink:href="pone.0009287.s002.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0009287.s003"><label>Table S2</label><caption><p>LMP2 60HH, HLA-A&#x0002a;02 and gender frequency in the second investigated Italian MS population (n&#x0200a;&#x0003d;&#x0200a;598) compared to age-matched Italian control population (n&#x0200a;&#x0003d;&#x0200a;845). (A) Gender distribution in MS patients and control populations. (B) LMP2 R60H polymorphism and allele distribution in MS and control HLA-A&#x0002a;02 carrier populations, taking into account the gender. (C) LMP2 R60H polymorphism and MS onset age in HLA-A&#x0002a;02-positive female MS patients. Values in brackets in distribution column are percentages. Statistical results are reported for each genetic analysis.</p><p>(0.14 MB DOC)</p></caption><media xlink:href="pone.0009287.s003.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We would like to thank Dr. Ulrike Kuckelkorn and Dr. Frederic Ebstein for supervision of proteasome purification and binding affinity assay, Prof. Annalisa Pession to have supervised the IHC experiments, Dr. Daniel Remondini for the statistical analysis support, Dr. Fabiola Olivieri for the logistic support, Paola Rosini and Laura Bergamaschi for genotyping, Donovan Payne and Roisin O'Connor for the linguistic revision of the manuscript.</p></ack><ref-list><title>References</title><ref id="pone.0009287-Friese1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friese</surname><given-names>MA</given-names></name><name><surname>Fugger</surname><given-names>L</given-names></name></person-group><year>2005</year><article-title>Autoreactive CD8&#x0002b; T cells in multiple sclerosis: a new target for therapy?</article-title><source>Brain</source><volume>128</volume><fpage>1747</fpage><lpage>1763</lpage><pub-id pub-id-type="pmid">15975943</pub-id></mixed-citation></ref><ref id="pone.0009287-Giovannoni1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovannoni</surname><given-names>G</given-names></name><name><surname>Ebers</surname><given-names>G</given-names></name></person-group><year>2007</year><article-title>Multiple sclerosis: the environment and causation.</article-title><source>Curr Opin Neurol</source><volume>20</volume><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">17495618</pub-id></mixed-citation></ref><ref id="pone.0009287-Fugger1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fugger</surname><given-names>L</given-names></name><name><surname>Friese</surname><given-names>MA</given-names></name><name><surname>Bell</surname><given-names>JI</given-names></name></person-group><year>2009</year><article-title>From genes to function: the next challenge to understanding multiple sclerosis.</article-title><source>Nat Rev Immunol</source></mixed-citation></ref><ref id="pone.0009287-Friese2"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friese</surname><given-names>MA</given-names></name><name><surname>Jakobsen</surname><given-names>KB</given-names></name><name><surname>Friis</surname><given-names>L</given-names></name><name><surname>Etzensperger</surname><given-names>R</given-names></name><name><surname>Craner</surname><given-names>MJ</given-names></name><etal/></person-group><year>2008</year><article-title>Opposing effects of HLA class I molecules in tuning autoreactive CD8&#x0002b; T cells in multiple sclerosis.</article-title><source>Nat Med</source><volume>14</volume><fpage>1227</fpage><lpage>1235</lpage><pub-id pub-id-type="pmid">18953350</pub-id></mixed-citation></ref><ref id="pone.0009287-Kloetzel1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloetzel</surname><given-names>PM</given-names></name></person-group><year>2001</year><article-title>Antigen processing by the proteasome.</article-title><source>Nat Rev Mol Cell Biol</source><volume>2</volume><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">11265247</pub-id></mixed-citation></ref><ref id="pone.0009287-DiazHernandez1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Hernandez</surname><given-names>M</given-names></name><name><surname>Hernandez</surname><given-names>F</given-names></name><name><surname>Martin-Aparicio</surname><given-names>E</given-names></name><name><surname>Gomez-Ramos</surname><given-names>P</given-names></name><name><surname>Moran</surname><given-names>MA</given-names></name><etal/></person-group><year>2003</year><article-title>Neuronal induction of the immunoproteasome in Huntington's disease.</article-title><source>J Neurosci</source><volume>23</volume><fpage>11653</fpage><lpage>11661</lpage><pub-id pub-id-type="pmid">14684867</pub-id></mixed-citation></ref><ref id="pone.0009287-Mishto1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishto</surname><given-names>M</given-names></name><name><surname>Bellavista</surname><given-names>E</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Stolzing</surname><given-names>A</given-names></name><name><surname>Ligorio</surname><given-names>C</given-names></name><etal/></person-group><year>2006</year><article-title>Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains.</article-title><source>Neurobiol Aging</source><volume>27</volume><fpage>54</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">16298241</pub-id></mixed-citation></ref><ref id="pone.0009287-Mishto2"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishto</surname><given-names>M</given-names></name><name><surname>Luciani</surname><given-names>F</given-names></name><name><surname>Holzhutter</surname><given-names>HG</given-names></name><name><surname>Bellavista</surname><given-names>E</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><etal/></person-group><year>2008</year><article-title>Modeling the in vitro 20S proteasome activity: the effect of PA28-alphabeta and of the sequence and length of polypeptides on the degradation kinetics.</article-title><source>J Mol Biol</source><volume>377</volume><fpage>1607</fpage><lpage>1617</lpage><pub-id pub-id-type="pmid">18336834</pub-id></mixed-citation></ref><ref id="pone.0009287-Kramer1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>U</given-names></name><name><surname>Illig</surname><given-names>T</given-names></name><name><surname>Grune</surname><given-names>T</given-names></name><name><surname>Krutmann</surname><given-names>J</given-names></name><name><surname>Esser</surname><given-names>C</given-names></name></person-group><year>2007</year><article-title>Strong associations of psoriasis with antigen processing LMP and transport genes TAP differ by gender and phenotype.</article-title><source>Genes Immun</source><volume>8</volume><fpage>513</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">17581627</pub-id></mixed-citation></ref><ref id="pone.0009287-Maksymowych1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maksymowych</surname><given-names>WP</given-names></name><name><surname>Tao</surname><given-names>S</given-names></name><name><surname>Vaile</surname><given-names>J</given-names></name><name><surname>Suarez-Almazor</surname><given-names>M</given-names></name><name><surname>Ramos-Remus</surname><given-names>C</given-names></name><etal/></person-group><year>2000</year><article-title>LMP2 polymorphism is associated with extraspinal disease in HLA-B27 negative Caucasian and Mexican Mestizo patients with ankylosing spondylitis.</article-title><source>J Rheumatol</source><volume>27</volume><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">10648037</pub-id></mixed-citation></ref><ref id="pone.0009287-VargasAlarcon1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vargas-Alarcon</surname><given-names>G</given-names></name><name><surname>Gamboa</surname><given-names>R</given-names></name><name><surname>Zuniga</surname><given-names>J</given-names></name><name><surname>Fragoso</surname><given-names>JM</given-names></name><name><surname>Hernandez-Pacheco</surname><given-names>G</given-names></name><etal/></person-group><year>2004</year><article-title>Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis.</article-title><source>Hum Immunol</source><volume>65</volume><fpage>1437</fpage><lpage>1442</lpage><pub-id pub-id-type="pmid">15603870</pub-id></mixed-citation></ref><ref id="pone.0009287-Mishto3"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishto</surname><given-names>M</given-names></name><name><surname>Bonafe</surname><given-names>M</given-names></name><name><surname>Salvioli</surname><given-names>S</given-names></name><name><surname>Olivieri</surname><given-names>F</given-names></name><name><surname>Franceschi</surname><given-names>C</given-names></name></person-group><year>2002</year><article-title>Age dependent impact of LMP polymorphisms on TNFalpha-induced apoptosis in human peripheral blood mononuclear cells.</article-title><source>Exp Gerontol</source><volume>37</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">11772516</pub-id></mixed-citation></ref><ref id="pone.0009287-Jurewicz1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurewicz</surname><given-names>A</given-names></name><name><surname>Biddison</surname><given-names>WE</given-names></name><name><surname>Antel</surname><given-names>JP</given-names></name></person-group><year>1998</year><article-title>MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes.</article-title><source>J Immunol</source><volume>160</volume><fpage>3056</fpage><lpage>3059</lpage><pub-id pub-id-type="pmid">9510211</pub-id></mixed-citation></ref><ref id="pone.0009287-Tsuchida1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchida</surname><given-names>T</given-names></name><name><surname>Parker</surname><given-names>KC</given-names></name><name><surname>Turner</surname><given-names>RV</given-names></name><name><surname>McFarland</surname><given-names>HF</given-names></name><name><surname>Coligan</surname><given-names>JE</given-names></name><etal/></person-group><year>1994</year><article-title>Autoreactive CD8&#x0002b; T-cell responses to human myelin protein-derived peptides.</article-title><source>Proc Natl Acad Sci U S A</source><volume>91</volume><fpage>10859</fpage><lpage>10863</lpage><pub-id pub-id-type="pmid">7526383</pub-id></mixed-citation></ref><ref id="pone.0009287-Zang1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zang</surname><given-names>YC</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Rivera</surname><given-names>VM</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>RR</given-names></name><etal/></person-group><year>2004</year><article-title>Increased CD8&#x0002b; cytotoxic T cell responses to myelin basic protein in multiple sclerosis.</article-title><source>J Immunol</source><volume>172</volume><fpage>5120</fpage><lpage>5127</lpage><pub-id pub-id-type="pmid">15067096</pub-id></mixed-citation></ref><ref id="pone.0009287-McDonald1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>WI</given-names></name><name><surname>Compston</surname><given-names>A</given-names></name><name><surname>Edan</surname><given-names>G</given-names></name><name><surname>Goodkin</surname><given-names>D</given-names></name><name><surname>Hartung</surname><given-names>HP</given-names></name><etal/></person-group><year>2001</year><article-title>Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.</article-title><source>Ann Neurol</source><volume>50</volume><fpage>121</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">11456302</pub-id></mixed-citation></ref><ref id="pone.0009287-Valmori1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valmori</surname><given-names>D</given-names></name><name><surname>Fonteneau</surname><given-names>JF</given-names></name><name><surname>Lizana</surname><given-names>CM</given-names></name><name><surname>Gervois</surname><given-names>N</given-names></name><name><surname>Lienard</surname><given-names>D</given-names></name><etal/></person-group><year>1998</year><article-title>Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.</article-title><source>J Immunol</source><volume>160</volume><fpage>1750</fpage><lpage>1758</lpage><pub-id pub-id-type="pmid">9469433</pub-id></mixed-citation></ref><ref id="pone.0009287-Klare1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klare</surname><given-names>N</given-names></name><name><surname>Seeger</surname><given-names>M</given-names></name><name><surname>Janek</surname><given-names>K</given-names></name><name><surname>Jungblut</surname><given-names>PR</given-names></name><name><surname>Dahlmann</surname><given-names>B</given-names></name></person-group><year>2007</year><article-title>Intermediate-type 20 S proteasomes in HeLa cells: &#x0201c;asymmetric&#x0201d; subunit composition, diversity and adaptation.</article-title><source>J Mol Biol</source><volume>373</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">17804016</pub-id></mixed-citation></ref><ref id="pone.0009287-Kloss1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloss</surname><given-names>A</given-names></name><name><surname>Meiners</surname><given-names>S</given-names></name><name><surname>Ludwig</surname><given-names>A</given-names></name><name><surname>Dahlmann</surname><given-names>B</given-names></name></person-group><year>2009</year><article-title>Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors.</article-title><source>Cardiovasc Res</source><volume>85</volume><fpage>367</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">19564153</pub-id></mixed-citation></ref><ref id="pone.0009287-Frischer1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frischer</surname><given-names>JM</given-names></name><name><surname>Bramow</surname><given-names>S</given-names></name><name><surname>Dal-Bianco</surname><given-names>A</given-names></name><name><surname>Lucchinetti</surname><given-names>CF</given-names></name><name><surname>Rauschka</surname><given-names>H</given-names></name><etal/></person-group><year>2009</year><article-title>The relation between inflammation and neurodegeneration in multiple sclerosis brains.</article-title><source>Brain</source><volume>132</volume><fpage>1175</fpage><lpage>1189</lpage><pub-id pub-id-type="pmid">19339255</pub-id></mixed-citation></ref><ref id="pone.0009287-Karadottir1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karadottir</surname><given-names>R</given-names></name><name><surname>Hamilton</surname><given-names>NB</given-names></name><name><surname>Bakiri</surname><given-names>Y</given-names></name><name><surname>Attwell</surname><given-names>D</given-names></name></person-group><year>2008</year><article-title>Spiking and nonspiking classes of oligodendrocyte precursor glia in CNS white matter.</article-title><source>Nat Neurosci</source><volume>11</volume><fpage>450</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">18311136</pub-id></mixed-citation></ref><ref id="pone.0009287-Mishto4"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishto</surname><given-names>M</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Bellavista</surname><given-names>E</given-names></name><name><surname>Sessions</surname><given-names>R</given-names></name><name><surname>Textoris-Taube</surname><given-names>K</given-names></name><etal/></person-group><year>2006</year><article-title>A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms.</article-title><source>Biol Chem</source><volume>387</volume><fpage>417</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">16606340</pub-id></mixed-citation></ref><ref id="pone.0009287-Kuckelkorn1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuckelkorn</surname><given-names>U</given-names></name><name><surname>Frentzel</surname><given-names>S</given-names></name><name><surname>Kraft</surname><given-names>R</given-names></name><name><surname>Kostka</surname><given-names>S</given-names></name><name><surname>Groettrup</surname><given-names>M</given-names></name><etal/></person-group><year>1995</year><article-title>Incorporation of major histocompatibility complex&#x02013;encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma.</article-title><source>Eur J Immunol</source><volume>25</volume><fpage>2605</fpage><lpage>2611</lpage><pub-id pub-id-type="pmid">7589133</pub-id></mixed-citation></ref><ref id="pone.0009287-Lewontin1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewontin</surname><given-names>RC</given-names></name><name><surname>Feldman</surname><given-names>MW</given-names></name></person-group><year>1988</year><article-title>A general asymptotic property of two-locus selection models.</article-title><source>Theor Popul Biol</source><volume>34</volume><fpage>177</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">3232120</pub-id></mixed-citation></ref><ref id="pone.0009287-Devlin1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devlin</surname><given-names>B</given-names></name><name><surname>Risch</surname><given-names>N</given-names></name></person-group><year>1995</year><article-title>A comparison of linkage disequilibrium measures for fine-scale mapping.</article-title><source>Genomics</source><volume>29</volume><fpage>311</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">8666377</pub-id></mixed-citation></ref><ref id="pone.0009287-Barrett1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><year>2005</year><article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title><source>Bioinformatics</source><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id></mixed-citation></ref><ref id="pone.0009287-Stohwasser1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stohwasser</surname><given-names>R</given-names></name><name><surname>Giesebrecht</surname><given-names>J</given-names></name><name><surname>Kraft</surname><given-names>R</given-names></name><name><surname>Muller</surname><given-names>EC</given-names></name><name><surname>Hausler</surname><given-names>KG</given-names></name><etal/></person-group><year>2000</year><article-title>Biochemical analysis of proteasomes from mouse microglia: induction of immunoproteasomes by interferon-gamma and lipopolysaccharide.</article-title><source>Glia</source><volume>29</volume><fpage>355</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">10652445</pub-id></mixed-citation></ref><ref id="pone.0009287-Perchellet1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perchellet</surname><given-names>A</given-names></name><name><surname>Brabb</surname><given-names>T</given-names></name><name><surname>Goverman</surname><given-names>JM</given-names></name></person-group><year>2008</year><article-title>Crosspresentation by nonhematopoietic and direct presentation by hematopoietic cells induce central tolerance to myelin basic protein.</article-title><source>Proc Natl Acad Sci U S A</source><volume>105</volume><fpage>14040</fpage><lpage>14045</lpage><pub-id pub-id-type="pmid">18772374</pub-id></mixed-citation></ref><ref id="pone.0009287-Perchellet2"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perchellet</surname><given-names>A</given-names></name><name><surname>Stromnes</surname><given-names>I</given-names></name><name><surname>Pang</surname><given-names>JM</given-names></name><name><surname>Goverman</surname><given-names>J</given-names></name></person-group><year>2004</year><article-title>CD8&#x0002b; T cells maintain tolerance to myelin basic protein by &#x02018;epitope theft&#x02019;.</article-title><source>Nat Immunol</source><volume>5</volume><fpage>606</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">15146180</pub-id></mixed-citation></ref><ref id="pone.0009287-Strehl1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strehl</surname><given-names>B</given-names></name><name><surname>Seifert</surname><given-names>U</given-names></name><name><surname>Kruger</surname><given-names>E</given-names></name><name><surname>Heink</surname><given-names>S</given-names></name><name><surname>Kuckelkorn</surname><given-names>U</given-names></name><etal/></person-group><year>2005</year><article-title>Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing.</article-title><source>Immunol Rev</source><volume>207</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">16181324</pub-id></mixed-citation></ref><ref id="pone.0009287-TextorisTaube1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Textoris-Taube</surname><given-names>K</given-names></name><name><surname>Henklein</surname><given-names>P</given-names></name><name><surname>Pollmann</surname><given-names>S</given-names></name><name><surname>Bergann</surname><given-names>T</given-names></name><name><surname>Weisshoff</surname><given-names>H</given-names></name><etal/></person-group><year>2007</year><article-title>The N-terminal flanking region of the TRP2360-368 melanoma antigen determines proteasome activator PA28 requirement for epitope liberation.</article-title><source>J Biol Chem</source><volume>282</volume><fpage>12749</fpage><lpage>12754</lpage><pub-id pub-id-type="pmid">17308306</pub-id></mixed-citation></ref><ref id="pone.0009287-Bergamaschi1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergamaschi</surname><given-names>L</given-names></name><name><surname>Leone</surname><given-names>MA</given-names></name><name><surname>Fasano</surname><given-names>ME</given-names></name><name><surname>Guerini</surname><given-names>FR</given-names></name><name><surname>Ferrante</surname><given-names>D</given-names></name><etal/></person-group><year>2009</year><article-title>HLA-class I markers and multiple sclerosis susceptibility in the Italian population.</article-title><source>Genes Immun</source></mixed-citation></ref><ref id="pone.0009287-Brynedal1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brynedal</surname><given-names>B</given-names></name><name><surname>Duvefelt</surname><given-names>K</given-names></name><name><surname>Jonasdottir</surname><given-names>G</given-names></name><name><surname>Roos</surname><given-names>IM</given-names></name><name><surname>Akesson</surname><given-names>E</given-names></name><etal/></person-group><year>2007</year><article-title>HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis.</article-title><source>PLoS ONE</source><volume>2</volume><fpage>e664</fpage><pub-id pub-id-type="pmid">17653284</pub-id></mixed-citation></ref><ref id="pone.0009287-DAlfonso1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Alfonso</surname><given-names>S</given-names></name><name><surname>Bolognesi</surname><given-names>E</given-names></name><name><surname>Guerini</surname><given-names>FR</given-names></name><name><surname>Barizzone</surname><given-names>N</given-names></name><name><surname>Bocca</surname><given-names>S</given-names></name><etal/></person-group><year>2008</year><article-title>A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy.</article-title><source>Genes Immun</source><volume>9</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">17928868</pub-id></mixed-citation></ref><ref id="pone.0009287-Pastorino1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastorino</surname><given-names>R</given-names></name><name><surname>Menni</surname><given-names>C</given-names></name><name><surname>Barca</surname><given-names>M</given-names></name><name><surname>Foco</surname><given-names>L</given-names></name><name><surname>Saddi</surname><given-names>V</given-names></name><etal/></person-group><year>2009</year><article-title>Association between protective and deleterious HLA alleles with multiple sclerosis in Central East Sardinia.</article-title><source>PLoS One</source><volume>4</volume><fpage>e6526</fpage><pub-id pub-id-type="pmid">19654877</pub-id></mixed-citation></ref><ref id="pone.0009287-ElEtr1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Etr</surname><given-names>M</given-names></name><name><surname>Vukusic</surname><given-names>S</given-names></name><name><surname>Gignoux</surname><given-names>L</given-names></name><name><surname>Durand-Dubief</surname><given-names>F</given-names></name><name><surname>Achiti</surname><given-names>I</given-names></name><etal/></person-group><year>2005</year><article-title>Steroid hormones in multiple sclerosis.</article-title><source>J Neurol Sci</source><volume>233</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">15878598</pub-id></mixed-citation></ref><ref id="pone.0009287-Pelfrey1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelfrey</surname><given-names>CM</given-names></name><name><surname>Moldovan</surname><given-names>IR</given-names></name><name><surname>Cotleur</surname><given-names>AC</given-names></name><name><surname>Zamor</surname><given-names>N</given-names></name><name><surname>Rudick</surname><given-names>RA</given-names></name></person-group><year>2005</year><article-title>Effects of sex hormones on costimulatory molecule expression in multiple sclerosis.</article-title><source>J Neuroimmunol</source><volume>167</volume><fpage>190</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">16046001</pub-id></mixed-citation></ref><ref id="pone.0009287-Moldovan1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moldovan</surname><given-names>IR</given-names></name><name><surname>Cotleur</surname><given-names>AC</given-names></name><name><surname>Zamor</surname><given-names>N</given-names></name><name><surname>Butler</surname><given-names>RS</given-names></name><name><surname>Pelfrey</surname><given-names>CM</given-names></name></person-group><year>2008</year><article-title>Multiple sclerosis patients show sexual dimorphism in cytokine responses to myelin antigens.</article-title><source>J Neuroimmunol</source><volume>193</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">18022700</pub-id></mixed-citation></ref><ref id="pone.0009287-Liu1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Donahue</surname><given-names>KC</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Kurnellas</surname><given-names>MP</given-names></name><name><surname>Grant</surname><given-names>JE</given-names></name><etal/></person-group><year>2007</year><article-title>Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord.</article-title><source>J Proteome Res</source><volume>6</volume><fpage>2565</fpage><lpage>2575</lpage><pub-id pub-id-type="pmid">17571869</pub-id></mixed-citation></ref><ref id="pone.0009287-Papenfuss1"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papenfuss</surname><given-names>TL</given-names></name><name><surname>Thrash</surname><given-names>JC</given-names></name><name><surname>Danielson</surname><given-names>PE</given-names></name><name><surname>Foye</surname><given-names>PE</given-names></name><name><surname>Hllbrush</surname><given-names>BS</given-names></name><etal/></person-group><year>2007</year><article-title>Induction of Golli-MBP expression in CNS macrophages during acute LPS-induced CNS inflammation and experimental autoimmune encephalomyelitis (EAE).</article-title><source>ScientificWorldJournal</source><volume>7</volume><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">17982583</pub-id></mixed-citation></ref><ref id="pone.0009287-Bourdoulous1"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourdoulous</surname><given-names>S</given-names></name><name><surname>Beraud</surname><given-names>E</given-names></name><name><surname>Le Page</surname><given-names>C</given-names></name><name><surname>Zamora</surname><given-names>A</given-names></name><name><surname>Ferry</surname><given-names>A</given-names></name><etal/></person-group><year>1995</year><article-title>Anergy induction in encephalitogenic T cells by brain microvessel endothelial cells is inhibited by interleukin-1.</article-title><source>Eur J Immunol</source><volume>25</volume><fpage>1176</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">7539749</pub-id></mixed-citation></ref><ref id="pone.0009287-Risau1"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risau</surname><given-names>W</given-names></name><name><surname>Engelhardt</surname><given-names>B</given-names></name><name><surname>Wekerle</surname><given-names>H</given-names></name></person-group><year>1990</year><article-title>Immune function of the blood-brain barrier: incomplete presentation of protein (auto-)antigens by rat brain microvascular endothelium in vitro.</article-title><source>J Cell Biol</source><volume>110</volume><fpage>1757</fpage><lpage>1766</lpage><pub-id pub-id-type="pmid">1692329</pub-id></mixed-citation></ref><ref id="pone.0009287-Wilcox1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcox</surname><given-names>CE</given-names></name><name><surname>Healey</surname><given-names>DG</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>Willoughby</surname><given-names>DA</given-names></name><name><surname>Turk</surname><given-names>JL</given-names></name></person-group><year>1989</year><article-title>Presentation of myelin basic protein by normal guinea-pig brain endothelial cells and its relevance to experimental allergic encephalomyelitis.</article-title><source>Immunology</source><volume>67</volume><fpage>435</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">2475431</pub-id></mixed-citation></ref><ref id="pone.0009287-Galea1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galea</surname><given-names>I</given-names></name><name><surname>Bernardes-Silva</surname><given-names>M</given-names></name><name><surname>Forse</surname><given-names>PA</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Liblau</surname><given-names>RS</given-names></name><etal/></person-group><year>2007</year><article-title>An antigen-specific pathway for CD8 T cells across the blood-brain barrier.</article-title><source>J Exp Med</source><volume>204</volume><fpage>2023</fpage><lpage>2030</lpage><pub-id pub-id-type="pmid">17682068</pub-id></mixed-citation></ref><ref id="pone.0009287-Macagno1"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macagno</surname><given-names>A</given-names></name><name><surname>Gilliet</surname><given-names>M</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Nestle</surname><given-names>FO</given-names></name><etal/></person-group><year>1999</year><article-title>Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation.</article-title><source>Eur J Immunol</source><volume>29</volume><fpage>4037</fpage><lpage>4042</lpage><pub-id pub-id-type="pmid">10602014</pub-id></mixed-citation></ref><ref id="pone.0009287-Silva1"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>AM</given-names></name><name><surname>Bettencourt</surname><given-names>A</given-names></name><name><surname>Pereira</surname><given-names>C</given-names></name><name><surname>Santos</surname><given-names>E</given-names></name><name><surname>Carvalho</surname><given-names>C</given-names></name><etal/></person-group><year>2009</year><article-title>Protective role of the HLA-A&#x0002a;02 allele in Portuguese patients with multiple sclerosis.</article-title><source>Mult Scler</source><volume>15</volume><fpage>771</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">19482867</pub-id></mixed-citation></ref><ref id="pone.0009287-Mishto5"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishto</surname><given-names>M</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Bellavista</surname><given-names>E</given-names></name><name><surname>Bonafe</surname><given-names>M</given-names></name><name><surname>Monti</surname><given-names>D</given-names></name><etal/></person-group><year>2003</year><article-title>Immunoproteasomes and immunosenescence.</article-title><source>Ageing Res Rev</source><volume>2</volume><fpage>419</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">14522244</pub-id></mixed-citation></ref><ref id="pone.0009287-Meuth1"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meuth</surname><given-names>SG</given-names></name><name><surname>Kleinschnitz</surname><given-names>C</given-names></name><name><surname>Wiendl</surname><given-names>H</given-names></name></person-group><year>2008</year><article-title>Recent clinical trials and future therapies.</article-title><source>J Neurol</source><volume>255</volume><issue>Suppl 6</issue><fpage>93</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">19300967</pub-id></mixed-citation></ref><ref id="pone.0009287-Mishto6"><label>49</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mishto</surname><given-names>M</given-names></name><name><surname>Bellavista</surname><given-names>E</given-names></name><name><surname>Dyllick-Brenzinger</surname><given-names>M</given-names></name><name><surname>Dahlmann</surname><given-names>B</given-names></name><name><surname>Franceschi</surname><given-names>C</given-names></name></person-group><year>2009</year><article-title>Role of immunoproteasome in ageing and neurodegenerative diseases.</article-title><person-group person-group-type="editor"><name><surname>Di Napoli</surname><given-names>M</given-names></name><name><surname>Wojcik</surname><given-names>C</given-names></name></person-group><source>The ubiquitin proteasome system in the central nervous system: from physiology to pathology - The 2008 Update</source><publisher-loc>New York</publisher-loc><publisher-name>Nova Science Publishers</publisher-name></mixed-citation></ref><ref id="pone.0009287-Wehenkel1"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wehenkel</surname><given-names>M</given-names></name><name><surname>Hong</surname><given-names>JT</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name></person-group><year>2008</year><article-title>Proteasome modulators: essential chemical genetic tools for understanding human diseases.</article-title><source>Mol Biosyst</source><volume>4</volume><fpage>280</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">18354780</pub-id></mixed-citation></ref><ref id="pone.0009287-Muchamuel1"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muchamuel</surname><given-names>T</given-names></name><name><surname>Basler</surname><given-names>M</given-names></name><name><surname>Aujay</surname><given-names>MA</given-names></name><name><surname>Suzuki</surname><given-names>E</given-names></name><name><surname>Kalim</surname><given-names>KW</given-names></name><etal/></person-group><year>2009</year><article-title>A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.</article-title><source>Nat Med</source><volume>15</volume><fpage>781</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">19525961</pub-id></mixed-citation></ref><ref id="pone.0009287-Kuhn1"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>DJ</given-names></name><name><surname>Hunsucker</surname><given-names>SA</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Voorhees</surname><given-names>PM</given-names></name><name><surname>Orlowski</surname><given-names>M</given-names></name><etal/></person-group><year>2009</year><article-title>Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.</article-title><source>Blood</source><volume>113</volume><fpage>4667</fpage><lpage>4676</lpage><pub-id pub-id-type="pmid">19050304</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was financed in part by the grant Giovani Ricercatori 2007 from Italian Ministry of Health to MM, DG and FMB, by a grant from the European Commission Integrated Project PROTEOMAGE (FP6) to CF, by the finalized projects of Fondazione Italiana Sclerosi Multipla (FISM) cod. 2003/R26 and BioPharmaNet to CF and 2002/R/40 and 2005/R/10, 2008/R/11 (Genoa) to SD'A, by the University of Bologna (FRO) to MPF, by the Regione Piemonte (Ricerca Sanitaria Finalizzata Project and Ricerca Sanitaria Applicata-CIPE Project) to SD'A, by Associazione Amici del Centro Dino Ferrari and IRCCS Ospedale Maggiore Policlinico, Milano to DG and by the grants Sonderforschungsbereich (SFB-507, SFB-421) to PMK and US, the grants TR43 and Neurocure to PMK. MM benefited from the A.V. Humboldt PostDoc fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>